Inhibition of a novel fibrogenic factor Tl1a reverses established colonic fibrosis

Mucosal Immunology

Volumn 7, Issue 6, 2014, Pages 1492-1503

  Shih, D Q ^a   Zheng, L ^a,b   Zhang, X ^b   Zhang, H ^a,b   Kanazawa, Y ^a   Ichikawa, R ^a   Wallace, K L ^a   Chen, J ^a   Pothoulakis, C ^c   Koon, H W ^c   Targan, S R ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b HEBEI MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; DEATH RECEPTOR 3; INTERLEUKIN RECEPTOR; PROTEIN IL31RA; PROTEIN TL1A; SOMATOMEDIN C; TL1A ANTIBODY; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; IL31RA PROTEIN, HUMAN; IL31RA PROTEIN, MOUSE; NEUTRALIZING ANTIBODY; TNFRSF25 PROTEIN, HUMAN; TNFRSF25 PROTEIN, MOUSE; TNFSF15 PROTEIN, HUMAN; TNFSF15 PROTEIN, MOUSE; VASCULAR ENDOTHELIAL GROWTH INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLONIC FIBROSIS; CONTROLLED STUDY; FIBROBLAST; INTESTINAL FIBROSIS; MOUSE; MYOFIBROBLAST; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; COLON; CROHN DISEASE; DRUG EFFECTS; FIBROSIS; GENETICS; HUMAN; IMMUNOLOGY; KNOCKOUT MOUSE; PATHOLOGY;

ANIMALS; ANTIBODIES, NEUTRALIZING; COLON; CROHN DISEASE; FIBROSIS; HUMANS; MICE; MICE, KNOCKOUT; MYOFIBROBLASTS; RECEPTORS, INTERLEUKIN; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 25; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 15;

EID: 84908200305     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2014.37     Document Type: Article

References (36)

1. Cosnes, J. et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm. Bowel Dis. 8, 244-250 (2002).
2. Peyrin-Biroulet, L. & Lemann, M. Review article: remission rates achievable by current therapies for inflammatory bowel disease. Aliment. Pharmacol. Ther. 33, 870-879 (2011).
3. Johnson, L. A., Luke, A., Sauder, K., Moons, D. S., Horowitz, J. C. & Higgins, P. D. Intestinal fibrosis is reduced by early elimination of inflammation in a mouse model of IBD: impact of a ''Top-Down'' approach to intestinal fibrosis in mice. Inflamm. Bowel Dis. 18, 460-471 (2012).
4. Hardie, W. D., Le Cras, T. D., Jiang, K., Tichelaar, J. W., Azhar, M. & Korfhagen, T. R. Conditional expression of transforming growth factoralpha in adult mouse lung causes pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 286, L741-L749 (2004).
5. Lavaud, S. et al. Inflammation is probably not a prerequisite for renal interstitial fibrosis in normoglycemic obese rats. Am. J. Physiol. Renal Physiol. 280, F683-F694 (2001).
6. Koon, H. W. et al. Substance P modulates colitis-associated fibrosis. Am. J. Pathol. 177, 2300-2309 (2010).
7. Shih, D. Q. et al. Insights into TL1A and IBD pathogenesis. Adv. Exp. Med. Biol. 691, 279-288 (2011).
8. Picornell, Y., Mei, L., Taylor, K., Yang, H., Targan, S. R. & Rotter, J. I. TNFSF15 is an ethnic-specific IBD gene. Inflamm. Bowel Dis. 13, 1333-1338 (2007).
9. Michelsen, K. S. et al. IBD-associated TL1A gene (TNFSF15) haplotypes determine increased expression of TL1A protein. PLoS One 4, e4719 (2009).
10. Barrett, R. et al. Constitutive TL1A expression under colitogenic conditions modulates the severity and location of gut mucosal inflammation and induces fibrostenosis. Am. J. Pathol. 180, 636-649 (2012).
11. Hirano, A. et al. Association study of 71 European Crohn's disease susceptibility loci in a Japanese population. inflamm. Bowel Dis. 19, 526-533 (2013).
12. Meylan, F. et al. The TNF-family cytokine TL1A drives IL-13-dependent small intestinal inflammation. Mucosal Immunol. 4, 172-185 (2011).
13. Taraban, V. Y. et al. Sustained TL1A expression modulates effector and regulatory T-cell responses and drives intestinal goblet cell hyperplasia. Mucosal Immunol. 4, 186-196 (2011).
14. Shih, D. Q. et al. Constitutive TL1A (TNFSF15) expression on lymphoid or myeloid cells leads tomild intestinal inflammation and fibrosis. PLoS One 6, e16090 (2011).
15. Zheng, L. et al. Sustained Tl1a expression on both lymphoid and myeloid cells leads to mild spontaneous intestinal inflammation and fibrosis. Eur. J. Microbiol. Immunol. 3, 11-20 (2013).
16. Takedatsu, H. et al. TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation. Gastroenterology 135, 552-567 (2008).
17. Wynn, T. A. & Ramalingam, T. R. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat. Med. 18, 1028-1040 (2012).
18. Speca, S., Giusti, I., Rieder, F. & Latella, G. Cellular and molecular mechanisms of intestinal fibrosis. World J. Gastroenterol. 18, 3635-3661 (2012).
19. Iredale, J. P. et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J. Clin. Investig. 102, 538-549 (1998).
20. Kisseleva, T. et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc. Natl Acad. Sci. USA 109, 9448-9453 (2012).
21. Dillon, S. R. et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat. Immunol. 5, 752-760 (2004).
22. Bilsborough, J., Mudri, S., Chadwick, E., Harder, B. & Dillon, S. R. IL-31 receptor (IL-31RA) knockout mice exhibit elevated responsiveness to oncostatin M. J. Immunol. 185, 6023-6030 (2010).
23. Lei, Z. et al. SCF and IL-31 rather than IL-17 and BAFF are potential indicators in patients with allergic asthma. Allergy 63, 327-332 (2008).
24. Wong, C. K., Leung, K. M., Qiu, H. N., Chow, J. Y., Choi, A. O. & Lam, C. W. Activation of eosinophils interacting with dermal fibroblasts by pruritogenic cytokine IL-31 and alarmin IL-33: implications in atopic dermatitis. PLoS One 7, e29815 (2012).
25. Jawa, R. S. et al. Regulated expression of the IL-31 receptor in bronchial and alveolar epithelial cells, pulmonary fibroblasts, and pulmonary macrophages. J. Interferon Cytokine Res. 28, 207-219 (2008).
26. Yagi, Y. et al. Interleukin-31 stimulates production of inflammatory mediators from human colonic subepithelial myofibroblasts. Int. J. Mol. Med. 19, 941-946 (2007).
27. Chen, J. S. et al. Screening for genes associated with cardiac fibrosis induced by aldosterone. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 28, 350-353 (2012).
28. Louis, E. et al. Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease. Clin. Exp. Immunol. 120, 241-246 (2000).
29. Gao,Q. et al. Expression of matrix metalloproteinases-2 and-9 in intestinal tissue of patients with inflammatory bowel diseases. Dig. Liver Dis. 37, 584-592 (2005).
30. Heuschkel, R. B., MacDonald, T. T., Monteleone, G., Bajaj-Elliott, M., Smith, J. A. & Pender, S. L. Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease. Gut 47, 57-62 (2000).
31. Stawowy, P. et al. Regulation of matrix metalloproteinase MT1-MMP/ MMP-2 in cardiac fibroblasts by TGF-beta1 involves furin-convertase. Cardiovasc. Res. 63, 87-97 (2004).
32. Andres, P. G. & Friedman, L. S. Epidemiology and the natural course of inflammatory bowel disease. Gastroenterol. Clin. North Am. 28, 255-281. vii (1999).
33. Vermeire, S., van Assche, G. & Rutgeerts, P. Review article: altering the natural history of Crohn's disease-evidence for and against current therapies. Aliment. Pharmacol. Ther. 25, 3-12 (2007).
34. Cosnes, J., Gower-Rousseau,C., Seksik, P. &Cortot, A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 140, 1785-1794 (2011).
35. Vallance, B. A. et al. TGF-beta1 gene transfer to the mouse colon leads to intestinal fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 289, G116-G128 (2005).
36. Fang, L., Adkins, B., Deyev, V. & Podack, E. R. Essential role of TNF receptor superfamily 25 (TNFRSF25) in the development of allergic lung inflammation. J. Exp. Med. 205, 1037-1048 (2008).